To prevent periprosthetic joint infection (PJI), optimal penetration of antibiotics into the joint-space is needed. In revision arthroplasty, the incidence of PJI is increased compared to primary arthroplasty. In this study, the penetration of antibiotic agents into the synovial fluid and bone will be analyzed. The concentration of antibiotics will be related tot the to the susceptibility (minimal inhibitory concentration; MIC-90) of microorganisms that frequently cause PJI.
Periprosthetic joint infection (PJI) is a feared complication of joint replacement, with an incidence of 0.5-1% after primary joint replacement and 3-5% after revision arthroplasty. For orthopaedic surgery involving a prosthesis, the administration of systemic antibiotic prophylaxis is strongly recommended to prevent PJI. Cefazolin is widely used as agent of choice in surgical antibiotic prophylaxis. Previous studies, all performed in patients undergoing primary joint replacement, demonstrated that the concentration of cefazolin in bone and synovial fluid was dose-dependent and exceeds the MIC90 for methicillin susceptible Staphylococcus aureus (MSSA), when given as 1 to 4 gram single dose shortly before incision. When a PJI is already present, clindamycin is used as treatment option in PJI caused by staphylococci (when combined with rifampicin) or cutibacteria. A limited number of studies have been performed to analyse the penetration of clindamycin into bone. These studies showed that clindamycin penetrates well into the bone and concentrations exceeded the MIC90 for MSSA. No studies have been performed to analyse the penetration of antibiotic agents into the periarticular tissue in patients who will undergo revision arthroplasty. In revision arthroplasty a foreign body (prosthesis) is in situ and periarticular tissue condition can be compromised due to previous surgical procedures and the presence of bone reaction to the prosthesis. It is not known whether the difference in PJI incidence after primary and revision arthroplasty may be explained by different penetration of the surgical antibiotic prophylaxis. The aim of this explorative study is to analyse the penetration of cefazolin and clindamycin into synovial fluid and bone and whether the concentration of the agents exceeds the MIC90 for micro-organisms frequently causing PJI.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
30
During the reimplantation, 3 serum samples will be taken at different timepoint during the procedure.
During the reimplantation 1 synovial fluid sample will be taken prior to incision.
During the reimplantation 2 cortical bone samples will be taken at different timepoints during the procedure.
penetration cefazolin into synovial fluid
The ratio (%) of the concentration of cefazolin in synovial fluid to serum.
Time frame: during surgical procedure prior to incision the synovial fluid sample will be taken
penetration cefazolin into bone tissue
The ratio (%) of the concentration of cefazolin in synovial fluid to serum.
Time frame: during surgical procedure prior to incision the synovial fluid sample will be taken
penetration clindamycin into bone tissue
The ratio (%) of the concentration of cefazolin in bone tissue to serum.
Time frame: during surgical procedure, directly after opening the joint and before reimplantation of the prosthesis the bone samples will be taken
AUC/MIC90 of cefazolin
The ratio of area under the curve of cefazolin to the minimal inhibitory concentration-90 of microorganisms
Time frame: sampling during procedure
AUC/MIC90 of clindamycin
The ratio of area under the curve of cefazolin to the minimal inhibitory concentration-90 of microorganisms
Time frame: sampling during procedure
factors associated with reduced cefazolin concentration
univariable and multivariable (if possible) analysis for factors that are associated with reduced concentration of cefazolin (i.e., BMI, age, ..)
Time frame: sampling during procedure
factors associated with reduced clindamycin concentration
univariable and multivariable (if possible) analysis for factors that are associated with reduced concentration of cefazolin (i.e., BMI, age, ..)
Time frame: sampling during procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.